A Novel System for the Quantification of the ADCC Activity of Therapeutic Antibodies

Figure 3

Comparison of the ADCC activity of rituximab using iLite effector cells V-variant or F-variant and wild type, CD20⁺, and CD20⁻ Raji target cells. iLite effector cells V-variant (1.2 × 10⁵ cells/well) were mixed with 4 × 10⁴ cells/well WT, CD20⁺, or CD20⁻ target cells (4 × 10⁴ cells/well) for 4 hours in the presence of increasing concentrations of rituximab. Results are expressed as FL activity in RLU (a). iLite effector cells, V-variant or F-variant (1.2 × 10⁵ cells/well) were mixed with CD20⁺ target cells (4 × 10⁴ cells/well) for 6 hours in the presence of increasing concentrations of rituximab (b) prior to the addition of Nano-Glo Dual-luciferase reagent (Promega, Madison, WI) and the sequential determination of FL and NL activity. Results are expressed as fold induction.

(a)

(b)